Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Neurology and Neuroscience Reports
Published in: Current Neurology and Neuroscience Reports 6/2018

01-06-2018 | Movement Disorders (S Fox, Section Editor)

Disturbances of Sleep and Alertness in Parkinson’s Disease

Author: Aleksandar Videnovic

Published in: Current Neurology and Neuroscience Reports | Issue 6/2018

Login to get access

Abstract

Purpose of Review

Parkinson’s disease (PD) is the second most common neurodegenerative disorder. Sleep dysfunction is one of the most common non-motor manifestations of PD that has gained significant interest over the past two decades due to its impact on the daily lives of PD patients, poorly understood mechanisms, and limited treatment options. In this review, we discuss the most common sleep disorders in PD and present recent investigations that have broadened our understanding of the epidemiology, clinical manifestations, diagnosis, and treatment of disturbed sleep and alertness in PD.

Resent Findings

The etiology of impaired sleep-wake cycles in PD is multifactorial. Sleep dysfunction in PD encompasses insomnia, REM sleep behavior disorder, sleep-disordered breathing, restless legs syndrome, and circadian dysregulation. Despite the high prevalence of sleep dysfunction in PD, evidence supporting the efficacy of treatment strategies is limited.

Summary

We are at the opportune time to advance our understanding of sleep dysfunction in PD, which will hopefully lead to mechanisms-driven interventions for better sleep and allow us to approach sleep as a modifiable therapeutic target for other non-motor and motor manifestations in PD.
Literature
1.
Vilensky JA, Duvosin RC, Gilman S. The diagnosis of postencephalitic parkinsonism at the neurological unit of Boston City Hospital, 1930-1981. Neurol Sci. 2011;32(2):343–6.PubMedCrossRef
2.
Frucht S, Rogers JD, Greene PE, Gordon MF, Fahn S. Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology. 1999;52(9):1908–10.PubMedCrossRef
3.
Schenck CH, Bundlie SR, Mahowald MW. Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behaviour disorder. Neurology. 1996;46(2):388–93.PubMedCrossRef
4.
• Videnovic A, Willis GL. Circadian system - A novel diagnostic and therapeutic target in Parkinson’s disease? Mov Disord. 2016;31(3):260–9. A comprehensive review about the circadian system and its function in PD. PubMedPubMedCentralCrossRef
5.
Ylikoski A, Martikainen K, Sieminski M, Partinen M. Parkinson's disease and insomnia. Neurol Sci. 2015;36(11):2003–10.PubMedCrossRef
6.
Duncan GW, Khoo TK, Yarnall AJ, O'Brien JT, Coleman SY, Brooks DJ, et al. Health-related quality of life in early Parkinson's disease: the impact of nonmotor symptoms. Mov Disord. 2014;29(2):195–202.PubMedCrossRef
7.
Gjerstad MD, Wentzel-Larsen T, Aarsland D, Larsen JP. Insomnia in Parkinson’s disease: frequency and progression over time. J Neurol Neurosurg Psychiatry. 2007;78(5):476–9.PubMedCrossRef
8.
Trenkwalder C, Kohnen R, Hogl B, Metta V, Sixel-Doring F, Frauscher B, et al. Parkinson's disease sleep scale--validation of the revised version PDSS-2. Mov Disord. 2011;26(4):644–52.PubMedCrossRef
9.
Martinez-Martin P, Visser M, Rodriguez-Blazquez C, Marinus J, Chaudhuri KR, SCOPA-sleep v HJJ. PDSS: two scales for assessment of sleep disorder in Parkinson's disease. Mov Disord. 2008;23(12):1681–8.PubMedCrossRef
10.
11.
Seppi K, Weintraub D, Coelho M, Perez-Lloret S, Fox SH, Katzenschlager R, et al. The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson’s disease. Mov Disord. 2011;26(Suppl 3):S42–80.PubMedPubMedCentralCrossRef
12.
Trenkwalder C, Kies B, Rudzinska M, Fine J, Nikl J, Honczarenko K, et al. Rotigotine effects on early morning motor function and sleep in Parkinson's disease: a double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord. 2011;26(1):90–9.PubMedCrossRef
13.
Pierantozzi M, Placidi F, Liguori C, Albanese M, Imbriani P, Marciani MG, et al. Rotigotine may improve sleep architecture in Parkinson's disease: a double-blind, randomized, placebo-controlled polysomnographic study. Sleep Med. 2016;21:140–4.PubMedCrossRef
14.
Richard IH, McDermott MP, Kurlan R, Lyness JM, Como PG, Pearson N, et al. A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. Neurology. 2012;78(16):1229–36.PubMedPubMedCentralCrossRef
15.
Dobkin RD, Menza M, Bienfait KL, Gara M, Marin H, Mark MH, et al. Depression in Parkinson's disease: symptom improvement and residual symptoms after acute pharmacologic management. Am J Geriatr Psychiatry. 2011;19(3):222–9.PubMedPubMedCentralCrossRef
16.
Yang H, Petrini M. Effect of cognitive behavior therapy on sleep disorder in Parkinson's disease in China: a pilot study. Nurs Health Sci. 2012;14(4):458–63.PubMedCrossRef
17.
Rios Romenets S, Creti L, Fichten C, Bailes S, Libman E, Pelletier A, et al. Doxepin and cognitive behavioural therapy for insomnia in patients with Parkinson's disease -- a randomized study. Parkinsonism Relat Disord. 2013;19(7):670–5.PubMedCrossRef
18.
Humbert M, Findley J, Hernandez-Con M, Chahine LM. Cognitive behavioral therapy for insomnia in Parkinson's disease: a case series. NPJ Parkinson’s Dis. 2017;3:25.CrossRef
19.
Videnovic A, Klerman EB, Wang W, Marconi A, Kuhta T, Zee PC. Timed light therapy for sleep and daytime sleepiness associated with Parkinson disease: a randomized clinical trial. JAMA Neurol. 2017;74:411–8.PubMedPubMedCentralCrossRef
20.
Amara AW, Standaert DG, Guthrie S, Cutter G, Watts RL, Walker H. Unilateral subthalamic nucleus deep brain stimulation improves sleep quality in Parkinson’s disease. Park Relat Disord. 2011.
21.
22.
Medicine AAoS. The International Classification of Sleep Disorders: Diagnostic and Coding Manual. American Academy of Sleep Medicine. 2014;3rd ed. Rev. ed. Darien, IL.
23.
Allen RP, Picchietti D, Hening WA, Trenkwalder C, Walters AS, Montplaisi J. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med. 2003;4(2):101–19.PubMedCrossRef
24.
Walters AS. Toward a better definition of the restless legs syndrome. The international restless legs syndrome study group. Mov Disord. 1995;10(5):634–42.PubMedCrossRef
25.
Allen RP, Picchietti DL, Garcia-Borreguero D, Ondo WG, Walters AS, Winkelman JW, et al. Restless legs syndrome/Willis-Ekbom disease diagnostic criteria: updated international restless legs syndrome study group (IRLSSG) consensus criteria--history, rationale, description, and significance. Sleep Med. 2014;15(8):860–73.PubMedCrossRef
26.
Moccia M, Erro R, Picillo M, Santangelo G, Spina E, Allocca R, et al. A Four-Year Longitudinal Study on Restless Legs Syndrome in Parkinson Disease. Sleep. 2016;39(2):405–12.PubMedPubMedCentralCrossRef
27.
Shin HY, Youn J, Yoon WT, Kim JS, Cho JW. Restless legs syndrome in Korean patients with drug-naive Parkinson's disease: a nation-wide study. Parkinsonism Relat Disord. 2013;19(3):355–8.PubMedCrossRef
28.
Fereshtehnejad SM, Shafieesabet M, Shahidi GA, Delbari A, Lokk J. Restless legs syndrome in patients with Parkinson's disease: a comparative study on prevalence, clinical characteristics, quality of life and nutritional status. Acta Neurol Scand. 2015;131(4):211–8.PubMedCrossRef
29.
Covassin N, Neikrug AB, Liu L, Corey-Bloom J, Loredo JS, Palmer BW, et al. Clinical correlates of periodic limb movements in sleep in Parkinson's disease. J Neurol Sci. 2012;316(1–2):131–6.PubMedPubMedCentralCrossRef
30.
Linke R, Eisensehr I, Wetter TC, Gildehaus FJ, Popperl G, Trenkwalder C, et al. Presynaptic dopaminergic function in patients with restless legs syndrome: are there common features with early Parkinson's disease? Mov Disord. 2004;19(10):1158–62.PubMedCrossRef
31.
Kwon DY, Seo WK, Yoon HK, Park MH, Koh SB, Park KW. Transcranial brain sonography in Parkinson's disease with restless legs syndrome. Mov Disord. 2010;25(10):1373–8.PubMedCrossRef
32.
Ryu JH, Lee MS, Baik JS. Sonographic abnormalities in idiopathic restless legs syndrome (RLS) and RLS in Parkinson’s disease. Parkinsonism Relat Disord. 2011;17(3):201–3.PubMedCrossRef
33.
Lahut S, Vadasz D, Depboylu C, Ries V, Krenzer M, Stiasny-Kolster K, et al. The PD-associated alpha-synuclein promoter Rep1 allele 2 shows diminished frequency in restless legs syndrome. Neurogenetics. 2014;15(3):189–92.PubMedCrossRef
34.
Walters AS, LeBrocq C, Dhar A, Hening W, Rosen R, Allen RP, et al. Validation of the international restless legs syndrome study group rating scale for restless legs syndrome. Sleep Med. 2003;4(2):121–32.PubMedCrossRef
35.
Gjerstad MD, Tysnes OB, Larsen JP. Increased risk of leg motor restlessness but not RLS in early Parkinson disease. Neurology. 2011;77(22):1941–6.PubMedCrossRef
36.
De Cock VC, Bayard S, Yu H, Grini M, Carlander B, Postuma R, et al. Suggested immobilization test for diagnosis of restless legs syndrome in Parkinson's disease. Mov Disord. 2012;27(6):743–9.PubMedCrossRef
37.
Winkelman JW, Sethi KD, Kushida CA, Becker PM, Koester J, Cappola JJ, et al. Efficacy and safety of pramipexole in restless legs syndrome. Neurology. 2006;67(6):1034–9.PubMedCrossRef
38.
Ma JF, Wan Q, Hu XY, Sun SG, Wang WZ, Zhao ZX, et al. Efficacy and safety of pramipexole in chinese patients with restless legs syndrome: results from a multi-center, randomized, double-blind, placebo-controlled trial. Sleep Med. 2012;13(1):58–63.PubMedCrossRef
39.
Zhang J, Liu B, Zheng Y, Chu T, Yang Z. Pramipexole for Chinese people with primary restless legs syndrome: a 12-week multicenter, randomized, double-blind study. Sleep Med. 2015;16(1):181–5.PubMedCrossRef
40.
Stiasny-Kolster K, Kohnen R, Schollmayer E, Moller JC, Oertel WH. Patch application of the dopamine agonist rotigotine to patients with moderate to advanced stages of restless legs syndrome: a double-blind, placebo-controlled pilot study. Mov Disord. 2004;19(12):1432–8.PubMedCrossRef
41.
Oertel WH, Benes H, Garcia-Borreguero D, Hogl B, Poewe W, Montagna P, et al. Rotigotine transdermal patch in moderate to severe idiopathic restless legs syndrome: a randomized, placebo-controlled polysomnographic study. Sleep Med. 2010;11(9):848–56.PubMedCrossRef
42.
Walters AS, Ondo WG, Dreykluft T, Grunstein R, Lee D, Sethi K. Ropinirole is effective in the treatment of restless legs syndrome. TREAT RLS 2: a 12-week, double-blind, randomized, parallel-group, placebo-controlled study. Mov Disord. 2004;19(12):1414–23.PubMedCrossRef
43.
• Allen RP, Chen C, Garcia-Borreguero D, Polo O, DuBrava S, Miceli J, et al. Comparison of pregabalin with pramipexole for restless legs syndrome. N Engl J Med. 2014;370(7):621–31. An important clinical trial that highlights the role of pregabalin in the treatment of RLS. PubMedCrossRef
44.
Kushida CA, Walters AS, Becker P, Thein SG, Perkins AT, Roth T, et al. A randomized, double-blind, placebo-controlled, crossover study of XP13512/GSK1838262 in the treatment of patients with primary restless legs syndrome. Sleep. 2009;32(2):159–68.PubMedPubMedCentralCrossRef
45.
Walters AS, Ondo WG, Kushida CA, Becker PM, Ellenbogen AL, Canafax DM, et al. Gabapentin enacarbil in restless legs syndrome: a phase 2b, 2-week, randomized, double-blind, placebo-controlled trial. Clin Neuropharmacol. 2009;32(6):311–20.PubMedCrossRef
46.
Kushida CA, Becker PM, Ellenbogen AL, Canafax DM, Randomized BRW. Double-blind, placebo-controlled study of XP13512/GSK1838262 in patients with RLS. Neurology. 2009;72(5):439–46.PubMedCrossRef
47.
Lee DO, Ziman RB, Perkins AT, Poceta JS, Walters AS, Barrett RW. A randomized, double-blind, placebo-controlled study to assess the efficacy and tolerability of gabapentin enacarbil in subjects with restless legs syndrome. J Clin Sleep Med. 2011;7(3):282–92.PubMedPubMedCentral
48.
Garcia-Borreguero D, Patrick J, DuBrava S, Becker PM, Lankford A, Chen C, et al. Pregabalin versus pramipexole: effects on sleep disturbance in restless legs syndrome. Sleep. 2014;37(4):635–43.PubMedPubMedCentralCrossRef
49.
Driver-Dunckley E, Evidente VG, Adler CH, Hillman R, Hernandez J, Fletcher G, et al. Restless legs syndrome in Parkinson's disease patients may improve with subthalamic stimulation. Mov Disord. 2006;21(8):1287–9.PubMedCrossRef
50.
Chahine LM, Ahmed A, Sun Z. Effects of STN DBS for Parkinson's disease on restless legs syndrome and other sleep-related measures. Parkinsonism Relat Dis. 2011;17(3):208–11.CrossRef
51.
Valko PO, Hauser S, Sommerauer M, Werth E, Baumann CR. Observations on sleep-disordered breathing in idiopathic Parkinson’s disease. PLoS One. 2014;9(6):e100828.PubMedPubMedCentralCrossRef
52.
Neikrug AB, Maglione JE, Liu L, Natarajan L, Avanzino JA, Corey-Bloom J, et al. Effects of sleep disorders on the non-motor symptoms of Parkinson disease. J Clin Sleep Med. 2013;9(11):1119–29.PubMedPubMedCentral
53.
Yeh NC, Tien KJ, Yang CM, Wang JJ, Weng SF. Increased risk of Parkinson's disease in patients with obstructive sleep apnea: a population-based, propensity score-matched, longitudinal follow-up study. Medicine. 2016;95(2):e2293.PubMedPubMedCentralCrossRef
54.
• Chahine LM, Amara AW, Videnovic A. A systematic review of the literature on disorders of sleep and wakefulness in Parkinson's disease from 2005 to 2015. Sleep Med Rev. 2017;35:33–50. A comprehensive review of the literature related to sleep disruption in PD. PubMedCrossRef
55.
Harmell AL, Neikrug AB, Palmer BW, Avanzino JA, Liu L, Maglione JE, et al. Obstructive Sleep Apnea and Cognition in Parkinson's disease. Sleep Med. 2016;21:28–34.PubMedPubMedCentralCrossRef
56.
Mery VP, Lafontaine AL, Robinson A, Benedetti A, Kimoff RJ, Kaminska M. Treatment of Obstructive Sleep Apnea with Continuous Positive Airway Pressure Improves Non-motor Symptoms in Parkinson’s disease Patients [abstract]. J Park Dis. 2013;3(Supplement 1):109.
57.
Neikrug AB, Liu L, Avanzino JA, Maglione JE, Natarajan L, Bradley L, et al. Continuous positive airway pressure improves sleep and daytime sleepiness in patients with Parkinson disease and sleep apnea. Sleep. 2014;37(1):177–85.PubMedPubMedCentralCrossRef
58.
Postuma RB, Gagnon JF, Vendette M, Fantini ML, Massicotte-Marquez J, Montplaisir J. Quantifying the risk of neurodegenerative disease in idiopathic REM sleep behavior disorder. Neurology. 2009;72(15):1296–300.PubMedPubMedCentralCrossRef
59.
Abbott RD, Ross GW, White LR, Tanner CM, Masaki KH, Nelson JS, et al. Excessive daytime sleepiness and subsequent development of Parkinson disease. Neurology. 2005;65(9):1442–6.PubMedCrossRef
60.
Simuni T, Caspell-Garcia C, Coffey C, Chahine LM, Lasch S, Oertel WH, et al. Correlates of excessive daytime sleepiness in de novo Parkinson's disease: a case control study. Mov Disord. 2015;30(10):1371–81.PubMedPubMedCentralCrossRef
61.
Wienecke M, Werth E, Poryazova R, Baumann-Vogel H, Bassetti CL, Weller M, et al. Progressive dopamine and hypocretin deficiencies in Parkinson's disease: is there an impact on sleep and wakefulness? J Sleep Res. 2012;21(6):710–7.PubMedCrossRef
62.
Buskova J, Klempir J, Majerova V, Picmausova J, Sonka K, Jech R, et al. Sleep disturbances in untreated Parkinson's disease. J Neurol. 2011;258(12):2254–9.PubMedCrossRef
63.
Korner Y, Meindorfner C, Moller JC, Stiasny-Kolster K, Haja D, Cassel W, et al. Predictors of sudden onset of sleep in Parkinson's disease. Mov Disord. 2004;19(11):1298–305.PubMedCrossRef
64.
Pandey S, Bajaj BK, Wadhwa A, Anand KS. Impact of sleep quality on the quality of life of patients with Parkinson's disease: a questionnaire based study. Clin Neurol Neurosurg. 2016;148:29–34.PubMedCrossRef
65.
Qin Z, Zhang L, Sun F, Fang X, Meng C, Tanner C, et al. Health related quality of life in early Parkinson's disease: impact of motor and non-motor symptoms, results from Chinese levodopa exposed cohort. Parkinsonism Relat Disord. 2009;15(10):767–71.PubMedCrossRef
66.
Ozdilek B, Gunal DI. Motor and non-motor symptoms in Turkish patients with Parkinson's disease affecting family caregiver burden and quality of life. J Neuropsychiatry Clin Neurosci. 2012;24(4):478–83.PubMedCrossRef
67.
Suzuki K, Miyamoto M, Miyamoto T, Okuma Y, Hattori N, Kamei S, et al. Correlation between depressive symptoms and nocturnal disturbances in Japanese patients with Parkinson's disease. Parkinsonism Relat Disord. 2009;15(1):15–9.PubMedCrossRef
68.
Gong Y, Liu CF. An analysis of clinical characteristics and factors in Parkinson's disease patients with excessive daytime sleepiness. Zhonghua Nei Ke Za Zhi. 2016;55(7):515–9.PubMed
69.
Perez Lloret S, Rossi M, Merello M, Rascol O, Cardinali DP. Nonmotor symptoms groups in Parkinson's disease patients: results of a pilot, exploratory study. Parkinsons Dis. 2011;2011:473579.PubMedPubMedCentral
70.
Verbaan D, Marinus J, Visser M, van Rooden SM, Stiggelbout AM, van Hilten JJ. Patient-reported autonomic symptoms in Parkinson disease. Neurology. 2007;69(4):333–41.PubMedCrossRef
71.
Thannickal TC, Lai YY, Hypocretin SJM. (Orexin) cell loss in Parkinson's disease. Brain. 2007;130(Pt 6):1586–95.PubMedCrossRef
72.
Fronczek R, Overeem S, Lee SY, Hegeman IM, van Pelt J, van Duinen SG, et al. Hypocretin (orexin) loss and sleep disturbances in Parkinson’s Disease. Brain. 2008;131(Pt 1):e88.PubMed
73.
Matsui H, Nishinaka K, Oda M, Hara N, Komatsu K, Kubori T, et al. Heterogeneous factors in dementia with Parkinson's disease: IMP-SPECT study. Parkinsonism Relat Disord. 2007;13(3):174–81.PubMedCrossRef
74.
Kato S, Watanabe H, Senda J, Hirayama M, Ito M, Atsuta N, et al. Widespread cortical and subcortical brain atrophy in Parkinson's disease with excessive daytime sleepiness. J Neurol. 2011.
75.
Chung S, Bohnen NI, Albin RL, Frey KA, Muller ML, Chervin RD. Insomnia and sleepiness in Parkinson disease: associations with symptoms and comorbidities. J Clin Sleep Med. 2013;9(11):1131–7.PubMedPubMedCentral
76.
Bliwise DL, Trotti LM, Juncos JJ, Factor SA, Freeman A, Rye DB. Daytime REM sleep in Parkinson’s disease. Parkinsonism Relat Disord. 2013;19(1):101–3.PubMedCrossRef
77.
Bolitho SJ, Naismith SL, Salahuddin P, Terpening Z, Grunstein RR, Lewis SJ. Objective measurement of daytime napping, cognitive dysfunction and subjective sleepiness in Parkinson’s disease. PLoS One. 2013;8(11):e81233.PubMedPubMedCentralCrossRef
78.
Ondo WG, Fayle R, Atassi F, Jankovic J. Modafinil for daytime somnolence in Parkinson’s disease: double blind, placebo controlled parallel trial. J Neurol Neurosurg Psychiatry. 2005;76(12):1636–9.PubMedPubMedCentralCrossRef
79.
Adler CH, Caviness JN, Hentz JG, Lind M, Tiede J. Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson’s disease. Mov Disord. 2003;18(3):287–93.PubMedCrossRef
80.
Hogl B, Saletu M, Brandauer E, Glatzl S, Frauscher B, Seppi K, et al. Modafinil for the treatment of daytime sleepiness in Parkinson’s disease: a double-blind, randomized, crossover, placebo-controlled polygraphic trial. Sleep. 2002;25(8):905–9.PubMedCrossRef
81.
Ondo WG, Perkins T, Swick T, Hull KL Jr, Jimenez JE, Garris TS, et al. Sodium oxybate for excessive daytime sleepiness in Parkinson disease: an open-label polysomnographic study. Arch Neurol. 2008;65(10):1337–40.PubMedCrossRef
82.
Buchele F, Hackius M, Schreglmann SR, Omlor W, Werth E, Maric A, et al. Sodium Oxybate for Excessive Daytime Sleepiness and Sleep Disturbance in Parkinson Disease: A Randomized Clinical Trial. JAMA Neurol. 2017.
83.
Postuma RB, Anang J, Pelletier A, Joseph L, Moscovich M, Grimes D, et al. Caffeine as symptomatic treatment for Parkinson disease (cafe-PD): a randomized trial. Neurology. 2017;89(17):1795–803.PubMedCrossRef
84.
Suzuki K, Miyamoto M, Miyamoto T, Uchiyama T, Watanabe Y, Suzuki S, et al. Istradefylline improves daytime sleepiness in patients with Parkinson’s disease: an open-label, 3-month study. J Neurol Sci. 2017;380:230–3.PubMedCrossRef
85.
van Maanen A, Meijer AM, van der Heijden KB, Oort FJ. The effects of light therapy on sleep problems: a systematic review and meta-analysis. Sleep Med Rev. 2016;29:52–62.PubMedCrossRef
86.
Schenck CH, Bundlie SR, Ettinger MG, Mahowald MW. Chronic behavioral disorders of human REM sleep: a new category of parasomnia. Sleep. 1986 Jun;9(2):293–308.PubMedCrossRef
87.
• Hogl B, Stefani A, Videnovic A. Idiopathic REM sleep behaviour disorder and neurodegeneration - an update. Nat Rev Neurol. 2017; A comprehesnive review of the markers of neurodegeneration within RBD.
88.
Berg D, Postuma RB, Adler CH, Bloem BR, Chan P, Dubois B, et al. MDS research criteria for prodromal Parkinson’s disease. Mov Disord. 2015;30(12):1600–11.PubMedCrossRef
89.
Kang SH, Yoon IY, Lee SD, Han JW, Kim TH, Kim KW. REM sleep behavior disorder in the Korean elderly population: prevalence and clinical characteristics. Sleep. 2013;36(8):1147–52.PubMedPubMedCentralCrossRef
90.
Scaglione C, Vignatelli L, Plazzi G, Marchese R, Negrotti A, Rizzo G, et al. REM sleep behaviour disorder in Parkinson’s disease: a questionnaire-based study. Neurol Sci. 2005;25(6):316–21.PubMedCrossRef
91.
Wu YH, Liao YC, Chen YH, Chang MH, Lin CH. Risk of premotor symptoms in patients with newly diagnosed PD: a nationwide, population-based, case-control study in Taiwan. PLoS One. 2015;10(6):e0130282.PubMedPubMedCentralCrossRef
92.
Chaudhuri KR, Martinez-Martin P, Schapira AH, Stocchi F, Sethi K, Odin P, et al. International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson’s disease: the NMSQuest study. Mov Disord. 2006;21(7):916–23.PubMedCrossRef
93.
Sixel-Doring F, Trautmann E, Mollenhauer B, Trenkwalder C. Rapid eye movement sleep behavioral events: a new marker for neurodegeneration in early Parkinson disease? Sleep. 2014;37(3):431–8.PubMedPubMedCentralCrossRef
94.
Sixel-Doring F, Trautmann E, Mollenhauer B, Trenkwalder C. Associated factors for REM sleep behavior disorder in Parkinson disease. Neurology. 2011;77(11):1048–54.PubMedCrossRef
95.
96.
Plomhause L, Dujardin K, Duhamel A, Delliaux M, Derambure P, Defebvre L, et al. Rapid eye movement sleep behavior disorder in treatment-naive Parkinson disease patients. Sleep Med. 2013;14(10):1035–7.PubMedCrossRef
97.
Postuma RB, Berg D. Advances in markers of prodromal Parkinson disease. Nat Rev Neurol. 2016;12(11):622–34.PubMedCrossRef
98.
• Iranzo A, Fernandez-Arcos A, Tolosa E, Serradell M, Molinuevo JL, Valldeoriola F, et al. Neurodegenerative disorder risk in idiopathic REM sleep behavior disorder: study in 174 patients. PLoS One. 2014;9(2):e89741. An important longitudinal study of RBD progression into a synucleinopathy. PubMedPubMedCentralCrossRef
99.
• Postuma RB, Iranzo A, Hogl B, Arnulf I, Ferini-Strambi L, Manni R, et al. Risk factors for neurodegeneration in idiopathic rapid eye movement sleep behavior disorder: a multicenter study. Ann Neurol. 2015;77(5):830–9. An important longitudinal study of RBD progression into a synucleinopathy. PubMedPubMedCentralCrossRef
100.
Boeve BF, Silber MH, Ferman TJ, Lin SC, Benarroch EE, Schmeichel AM, et al. Clinicopathologic correlations in 172 cases of rapid eye movement sleep behavior disorder with or without a coexisting neurologic disorder. Sleep Med. 2013;14(8):754–62.PubMedPubMedCentralCrossRef
101.
Garcia-Lorenzo D, Longo-Dos Santos C, Ewenczyk C, Leu-Semenescu S, Gallea C, Quattrocchi G, et al. The coeruleus/subcoeruleus complex in rapid eye movement sleep behaviour disorders in Parkinson’s disease. Brain. 2013;136(Pt 7):2120–9.PubMedPubMedCentralCrossRef
102.
Boeve BF, Silber MH, Saper CB, Ferman TJ, Dickson DW, Parisi JE, et al. Pathophysiology of REM sleep behaviour disorder and relevance to neurodegenerative disease. Brain. 2007;130(Pt 11):2770–88.PubMedCrossRef
103.
Brooks PL, Peever JH, Impaired GABA. Glycine transmission triggers cardinal features of rapid eye movement sleep behavior disorder in mice. J Neurosci. 2011;31(19):7111–21.PubMedCrossRef
104.
Frauscher B, Gschliesser V, Brandauer E, Ulmer H, Peralta CM, Muller J, et al. Video analysis of motor events in REM sleep behavior disorder. Mov Disord. 2007;22(10):1464–70.PubMedCrossRef
105.
Sixel-Doring F, Schweitzer M, Mollenhauer B, Trenkwalder C. Intraindividual variability of REM sleep behavior disorder in Parkinson’s disease: a comparative assessment using a new REM sleep behavior disorder severity scale (RBDSS) for clinical routine. J Clin Sleep Med. 2011;7(1):75–80.PubMedPubMedCentral
106.
Gjerstad MD, Boeve B, Wentzel-Larsen T, Aarsland D, Larsen JP. Occurrence and clinical correlates of REM sleep behaviour disorder in patients with Parkinson’s disease over time. J Neurol Neurosurg Psychiatry. 2008;79(4):387–91.PubMedCrossRef
107.
Gong Y, Xiong KP, Mao CJ, Shen Y, Hu WD, Huang JY, et al. Clinical manifestations of Parkinson disease and the onset of rapid eye movement sleep behavior disorder. Sleep Med. 2014;15(6):647–53.PubMedCrossRef
108.
Postuma RB, Gagnon JF, Vendette M, Charland K, Montplaisir J. Manifestations of Parkinson disease differ in association with REM sleep behavior disorder. Mov Disord. 2008;23(12):1665–72.PubMedCrossRef
109.
Vendette M, Gagnon JF, Decary A, Massicotte-Marquez J, Postuma RB, Doyon J, et al. REM sleep behavior disorder predicts cognitive impairment in Parkinson disease without dementia. Neurology. 2007;69(19):1843–9.PubMedCrossRef
110.
Chahine LM, Xie SX, Simuni T, Tran B, Postuma R, Amara A, et al. Longitudinal changes in cognition in early Parkinson’s disease patients with REM sleep behavior disorder. Parkinsonism Relat Disord. 2016;27:102–6.PubMedPubMedCentralCrossRef
111.
Fantini ML, Farini E, Ortelli P, Zucconi M, Manconi M, Cappa S, et al. Longitudinal study of cognitive function in idiopathic REM sleep behavior disorder. Sleep. 2011;34(5):619–25.PubMedPubMedCentral
112.
Postuma RB, Bertrand JA, Montplaisir J, Desjardins C, Vendette M, Rios Romenets S, et al. Rapid eye movement sleep behavior disorder and risk of dementia in Parkinson’s disease: a prospective study. Mov Disord. 2012;27(6):720–6.PubMedCrossRef
113.
Anang JB, Nomura T, Romenets SR, Nakashima K, Gagnon JF, Postuma RB. Dementia predictors in Parkinson disease: a validation study. J Park Dis. 2017;7(1):159–62.CrossRef
114.
Hogl B, Stefani A. REM sleep behavior disorder (RBD): Update on diagnosis and treatment. Somnologie (Berl). 2017;21(Suppl 1):1–8.
115.
Stiasny-Kolster K, Mayer G, Schafer S, Moller JC, Heinzel-Gutenbrunner M, Oertel WH. The REM sleep behavior disorder screening questionnaire--a new diagnostic instrument. Mov Disord. 2007;22(16):2386–93.PubMedCrossRef
116.
Li SX, Wing YK, Lam SP, Zhang J, Yu MW, Ho CK, et al. Validation of a new REM sleep behavior disorder questionnaire (RBDQ-HK). Sleep Med. 2010;11(1):43–8.PubMedCrossRef
117.
Frauscher B, Ehrmann L, Zamarian L, Auer F, Mitterling T, Gabelia D, et al. Validation of the Innsbruck REM sleep behavior disorder inventory. Mov Disord. 2012;27(13):1673–8.PubMedCrossRef
118.
Boeve BF, Molano JR, Ferman TJ, Lin SC, Bieniek K, Tippmann-Peikert M, et al. Validation of the Mayo Sleep Questionnaire to screen for REM sleep behavior disorder in a community-based sample. J Clin Sleep Med. 2013;9(5):475–80.PubMedPubMedCentral
119.
Boeve BF, Molano JR, Ferman TJ, Smith GE, Lin SC, Bieniek K, et al. Validation of the Mayo sleep questionnaire to screen for REM sleep behavior disorder in an aging and dementia cohort. Sleep Med. 2011;12(5):445–53.PubMedPubMedCentralCrossRef
120.
Stiasny-Kolster K, Sixel-Doring F, Trenkwalder C, Heinzel-Gutenbrunner M, Seppi K, Poewe W, et al. Diagnostic value of the REM sleep behavior disorder screening questionnaire in Parkinson’s disease. Sleep Med. 2015;16(1):186–9.PubMedCrossRef
121.
Nomura T, Inoue Y, Kagimura T, Uemura Y, Nakashima K. Utility of the REM sleep behavior disorder screening questionnaire (RBDSQ) in Parkinson’s disease patients. Sleep Med. 2011;12(7):711–3.PubMedCrossRef
122.
Chahine LM, Daley J, Horn S, Colcher A, Hurtig H, Cantor C, et al. Questionnaire-based diagnosis of REM sleep behavior disorder in Parkinson’s disease. Mov Disord. 2013;28(8):1146–9.PubMedCrossRef
123.
Bolitho SJ, Naismith SL, Terpening Z, Grunstein RR, Melehan K, Yee BJ, et al. Investigating rapid eye movement sleep without atonia in Parkinson’s disease using the rapid eye movement sleep behavior disorder screening questionnaire. Mov Disord. 2014;29(6):736–42.PubMedCrossRef
124.
Aurora RN, Zak RS, Maganti RK, Auerbach SH, Casey KR, Chowdhuri S, et al. Best practice guide for the treatment of REM sleep behavior disorder (RBD). J Clin Sleep Med. 2010;6(1):85–95.PubMedPubMedCentral
125.
Gagnon JF, Postuma RB, Montplaisir J. Update on the pharmacology of REM sleep behavior disorder. Neurology. 2006;67(5):742–7.PubMedCrossRef
126.
Kunz D, Mahlberg R. A two-part, double-blind, placebo-controlled trial of exogenous melatonin in REM sleep behaviour disorder. J Sleep Res. 2010;19(4):591–6.PubMedCrossRef
127.
McCarter SJ, Boswell CL, St Louis EK, Dueffert LG, Slocumb N, Boeve BF, et al. Treatment outcomes in REM sleep behavior disorder. Sleep Med. 2013;14(3):237–42.PubMedPubMedCentralCrossRef
128.
Howell MJ, Arneson PA, Schenck CH. A novel therapy for REM sleep behavior disorder (RBD). J Clin Sleep Med. 2011;7(6):639–44A.PubMedPubMedCentral
129.
Airagnes G, Pelissolo A, Lavallee M, Flament M, Limosin F. Benzodiazepine misuse in the elderly: risk factors, consequences, and management. Curr Psychiatry Rep. 2016;18(10):89.PubMedCrossRef
130.
Di Giacopo R, Fasano A, Quaranta D, Della Marca G, Bove F, Bentivoglio AR. Rivastigmine as alternative treatment for refractory REM behavior disorder in Parkinson’s disease. Mov Disord. 2012;27(4):559–61.PubMedCrossRef
131.
Videnovic A, Lazar AS, Barker RA, Overeem S. ‘The clocks that time us’--circadian rhythms in neurodegenerative disorders. Nat Rev Neurol. 2014;10(12):683–93.PubMedPubMedCentralCrossRef
132.
Videnovic A, Marconi A, Noble C, Reid KJ, Kuhta T, Simuni T, et al. Circadian rhythm of melatonin secretion is altered in Parkinson’s disease. Neurology. 2011;76(9):A494–5.
133.
Willison LD, Kudo T, Loh DH, Kuljis D, Colwell CS. Circadian dysfunction may be a key component of the non-motor symptoms of Parkinson’s disease: insights from a transgenic mouse model. Exp Neurol. 2013;243:57–66.PubMedPubMedCentralCrossRef
134.
Hartmann A, Veldhuis JD, Deuschle M, Standhardt H, Heuser I. Twenty-four hour cortisol release profiles in patients with Alzheimer's and Parkinson’s disease compared to normal controls: ultradian secretory pulsatility and diurnal variation. Neurobiol Aging. 1997;18(3):285–9.PubMedCrossRef
135.
Oh YS, Kim JS, Park IS, Song IU, Son YM, Park JW, et al. Association between nocturnal/supine hypertension and restless legs syndrome in patients with Parkinson’s disease. J Neurol Sci. 2014;344(1–2):186–9.PubMedCrossRef
136.
Ejaz AA, Sekhon IS, Munjal S. Characteristic findings on 24-h ambulatory blood pressure monitoring in a series of patients with Parkinson’s disease. Eur J Intern Med. 2006;17(6):417–20.PubMedCrossRef
137.
Whitehead DL, Davies AD, Playfer JR, Turnbull CJ. Circadian rest-activity rhythm is altered in Parkinson's disease patients with hallucinations. Mov Disord. 2008;23(8):1137–45.PubMedCrossRef
138.
Suzuki K, Miyamoto T, Miyamoto M, Kaji Y, Takekawa H, Hirata K. Circadian variation of core body temperature in Parkinson disease patients with depression: a potential biological marker for depression in Parkinson disease. Neuropsychobiology. 2007;56(4):172–9.PubMedCrossRef
139.
Paus S, Schmitz-Hubsch T, Wullner U, Vogel A, Klockgether T, Abele M. Bright light therapy in Parkinson's disease: a pilot study. Mov Disord. 2007;22(10):1495–8.PubMedCrossRef
140.
Willis GL, Primary TEJ. Secondary features of Parkinson's disease improve with strategic exposure to bright light: a case series study. Chronobiol Int. 2007;24(3):521–37.PubMedCrossRef
Metadata
Title
Disturbances of Sleep and Alertness in Parkinson’s Disease
Author
Aleksandar Videnovic
Publication date
01-06-2018
Publisher
Springer US
Published in
Current Neurology and Neuroscience Reports / Issue 6/2018
Print ISSN: 1528-4042
Electronic ISSN: 1534-6293
DOI
https://doi.org/10.1007/s11910-018-0838-2

Other articles of this Issue 6/2018

Current Neurology and Neuroscience Reports 6/2018 Go to the issue

Headache (RB Halker, Section Editor)

An Up to Date Review of Pseudotumor Cerebri Syndrome

Epilepsy (CW Bazil, Section Editor)

Neurostimulation for Memory Enhancement in Epilepsy

Neuroimaging (N Pavese, Section Editor)

Present and Future of Ultra-High Field MRI in Neurodegenerative Disorders

Stroke (H Diener, Section Editor)

Circulating Troponin I Level in Patients with Acute Ischemic Stroke

Critical Care (SA Mayer, Section Editor)

Minimally Invasive Surgery for Intracerebral Hemorrhage

Headache (RB Halker, Section Editor)

Exercise Headache: a Review